Rationale, Design, and Baseline Characteristics of the VALIANT (COVID-19 in Older Adults: A Longitudinal Assessment) Cohort
===========================================================================================================================

* Andrew B. Cohen
* Gail J. McAvay
* Mary Geda
* Sumon Chattopadhyay
* Seohyuk Lee
* Denise Acampora
* Katy Araujo
* Peter Charpentier
* Thomas M. Gill
* Alexandra M. Hajduk
* Lauren E. Ferrante

## Abstract

**Background** Most older adults hospitalized with COVID-19 survive their acute illness. The impact of COVID-19 hospitalization on patient-centered outcomes, such as physical function, cognitive function, and symptoms, is not well understood. We sought to address this knowledge gap by collecting longitudinal data about these issues from a cohort of older adult survivors of COVID-19 hospitalization.

**Methods** We undertook a prospective study of community-living persons age ≥60 years who were hospitalized with COVID-19 from June 2020 to June 2021. A baseline interview was conducted during or up to two weeks after hospitalization. Follow-up interviews occurred at one, three, and six months post-discharge. In interviews, participants completed comprehensive assessments of physical and cognitive function, symptoms, and psychosocial factors. If a participant was too impaired to complete an interview, an abbreviated assessment was performed with a proxy. Additional information was collected from the electronic health record. Baseline characteristics of the cohort are reported here.

**Results** Among 341 participants, the mean age was 71.4 (SD 8.4) years, 51% were women, and 37% were of Black race or Hispanic ethnicity. Median length of hospitalization was 8 (IQR 6-12) days. All but 4% of participants required supplemental oxygen and 21% required a higher level of care in an intensive care unit or stepdown unit. Nearly half (47%) reported at least one disability in physical function, 45% demonstrated cognitive impairment, and 67% were pre-frail or frail. Participants reported a mean of 9 of 14 (SD 3) COVID-19-related symptoms.

**Conclusions** Older adults hospitalized with COVID-19 demonstrated high rates of baseline physical and cognitive impairment as well as high symptom burden. Longitudinal findings from this cohort will advance our understanding of outcome trajectories of great importance to older survivors of COVID-19.

Key words
*   COVID-19
*   physical function
*   cognition
*   symptoms

## Introduction

Older adults are much more likely than younger adults to experience serious illness with COVID-19. A study in New York City during the first wave of infection found that the odds of hospitalization for persons ≥75 years were almost 40 times higher than for those under age 65.1 The most recent data from the Centers for Disease Control and Prevention, reported on June 2, 2022, show that 74% of deaths — more than 748,000 — have occurred among Americans age 65 and older.2 This amounts to more than 1 in 100 older Americans.

Nonetheless, most older adults survive serious illness (i.e., illness requiring hospitalization) with COVID-19.3 There is reason to be concerned, however, that older survivors are at risk for substantial decline in their health and functional status and that they may develop impairments that last even after the pandemic wanes. Normal aging confers decreased physiologic reserve and diminished resilience in the face of acute stressors,4 and older adults are much more likely than younger adults to have multiple chronic medical conditions as well as other underlying vulnerabilities, such as frailty.5 Hospitalization with COVID-19 involves long periods of isolation from all but essential medical staff, during which patients are unable to leave their hospital rooms, are at increased risk for immobility,6 and experience profound social isolation.7 Delirium is also common.8 Upon discharge, there may be limited access to physical therapy and other rehabilitative services.9

There are few data from those who have been hospitalized with COVID-19 about the health outcomes that matter most to older patients, including preservation of cognition, maintaining physical function, and freedom from burdensome symptoms.10 This is in part because information about these issues is not collected in routine clinical care. To address this knowledge gap, we designed VALIANT (COVID-19 in Older Adults: A Longitudinal Assessment), a prospective longitudinal study of adults ≥ 60 years hospitalized with COVID-19 at five hospitals in Connecticut. We interviewed patients during or shortly after their hospitalization and then at one, three, and six months after hospital discharge in order to collect granular information across multiple health domains. We then linked these data to information from the electronic medical record. The resulting dataset will permit an unusually rich examination of outcomes and outcome trajectories among older adults who require hospitalization for COVID-19.

## Methods

### Study Overview

VALIANT is a prospective longitudinal study of community-living persons age ≥60 years who were hospitalized with COVID-19 at one of five hospitals within the Yale-New Haven Health System (YNHHS) from June 2020 to June 2021. During a baseline interview and assessment, conducted during hospital admission or within two weeks of discharge, we collected information about participants’ physical function, cognitive function, symptoms, and psychological and lifestyle factors. Data about the same issues were subsequently collected at follow-up interviews at one, three, and six months after discharge. All assessments occurred via phone or videoconferencing software. Patient-reported data were supplemented by data from the electronic health record. The study was approved by the Institutional Review Board at Yale University. Methods reporting is consistent with the STROBE guidelines.11

### Patient Screening and Eligibility

Trained research coordinators used the electronic health record to identify potential participants. Patients were eligible if they were at least 60 years old, hospitalized at a YNHHS hospital, and had a PCR-confirmed diagnosis of SARS-CoV-2 infection either during or directly prior to hospital admission. Patients were excluded if they had previously been hospitalized with COVID-19 and were subsequently readmitted, regardless of whether their SARS-CoV-2 test remained positive. We made an exception for patients who were readmitted within 7 days of hospital discharge from their initial (index) COVID-19 admission, because, in such cases, we considered the two hospitalizations to constitute a single episode of care. Patients were also excluded if they were long-term residents in a skilled nursing facility, had advanced dementia, did not speak English or Spanish, or had opted out of research. Additionally, because we wished to collect longitudinal data about persons who were not at the end of life, patients were excluded if they had “comfort measures only” orders or had a planned discharge to hospice. The charts of all patients enrolled in the study were reviewed by one of the three principal investigators (A.B.C., a geriatrician; A.M.H., an epidemiologist with training in aging research; and L.E.F., a critical care physician) to confirm their eligibility.

For potential participants for whom there was concern about decisional impairment, we conducted the University of California San Diego Brief Assessment for Capacity to Consent.12 If decisional impairment was confirmed, proxies were sought for the informed consent process, along with verbal assent from participants. Proxies were also sought for participants who were unable to consent due to severity of illness (e.g., those who were intubated).

Participants or proxies were contacted via phone or videoconferencing software by research coordinators who explained the study, answered questions, and completed a verbal informed consent process. Consent information sheets were mailed to the patient’s home.

### Assessment Schedule

All study assessments were completed via phone or videoconference for the convenience of participants and safety of the study team. A schedule of the study interviews appears in **Figure 1**. Participants underwent a baseline interview, conducted in English or Spanish, during their COVID-19 hospitalization or within two weeks of hospital discharge. Completion of the baseline interview was required for the participant to be considered enrolled in the study. We collected information about pre-hospitalization physical function, health status, symptoms, and psychological and lifestyle factors. We also performed cognitive testing, described in detail below. Proxies completed an abbreviated interview that omitted cognitive testing as well as certain measures that could only be reliably reported by patients, such as depressive and anxiety symptoms. Follow-up interviews containing the same or similar measures occurred at one, three, and six months from the date of hospital discharge or, for readmitted patients, from date of discharge from the readmission. Follow-up interviews were completed by patients whenever possible or by proxy. A summary of assessments at each time point appears in **Supplemental Table 1** and further details for select assessments appear in **Supplemental Table 2**.

![Figure 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/09/15/2022.09.14.22279932/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279932/F1)

Figure 1. 
Schedule of study assessments for VALIANT. The baseline interview occurred during hospitalization with COVID-19 or within 2 weeks of discharge. For patients who were discharged and readmitted within 7 days, the baseline interview could occur within 2 weeks of discharge from the readmission. Follow-up interviews occurred during 3-week windows that opened at 1 month (30 days), 3 months (90 days), and 6 months (180 days) after discharge. Each tick mark (“|”) in the figure represents one week.

### Primary Measures

#### Physical Function

Physical function was assessed using a 15-item scale that captures disability in seven basic activities of daily living (bathing, dressing, transferring from a chair, walking inside the house, eating, toileting, and grooming),13 five instrumental activities of daily living (shopping, housework, meal preparation, taking medications, and managing finances),14 and three mobility activities (walking a quarter mile, climbing a flight of stairs, and lifting or carrying ten pounds).15 During the baseline interview, participants were asked about disability in these 15 functional activities at one month prior to admission to evaluate their pre-illness status. Disability in each functional activity was defined as needing help from another person to complete the task. In follow-up assessments at one, three, and six months post-discharge, participants were asked about disability in the same 15 functional activities “at the present time.”

#### Cognitive Function

Cognition was assessed using the Montreal Cognitive Assessment (MoCA) 5-minute protocol,16 an abbreviated version of the MoCA that has been modified for administration by telephone. The MoCA 5-minute protocol measures attention, orientation, language, verbal learning and memory, and executive function. It displays psychometric properties similar to the full MoCA17 and utilizes a cutoff <22 (range, 0 to 30) to indicate cognitive impairment.

#### Symptoms

When data collection commenced in June 2020, a symptom assessment instrument specific to COVID-19 had not yet been developed. We therefore adapted an existing instrument commonly used to measure symptoms in older adults, the Edmonton Symptom Assessment System (ESAS).18 The ESAS measures the presence and severity of nine common symptoms, including fatigue, pain, and dyspnea. We added symptoms relevant to COVID-19, including cough, anosmia, and ageusia, to comprise a list of 14 symptoms. Given work suggesting that there is considerable variation in the intensity of symptoms among older persons,19 we also measured symptom severity, with “1” indicating that a symptom was mild, “2” indicating that it was moderate, and “3” indicating that it was severe, yielding a total symptom score ranging from 0 to 42.

### Secondary Measures

#### Health Status

Health status was assessed with selected questions from the Short Form-12.20 As with physical function, participants were asked to report on their health status at one month prior to admission during the baseline interview and on their health status at the present time during follow-up interviews.

#### Frailty

Frailty was assessed in accordance with the Fried phenotype,21 with two questions adapted for remote assessment (self-reported walking speed in lieu of a gait test and difficulty opening a jar in lieu of a grip strength test22) and the modified questions about low physical activity used in the National Health and Aging Trends Study.23 Frailty was assessed during the baseline and six-month interviews.

#### Sensory Impairments

Vision and hearing were measured using questions from the National Health and Aging Trends Study concerning self-reported impairments in function with or without use of aids.24 Hearing impairment was assessed at all time points, given its association with functional disability,25 whereas vision impairment was assessed only at baseline.

#### Psychosocial Function

Depressive and anxiety symptoms were assessed with the Patient Health Questionnaire (PHQ-4).26 Social support was measured with a five-item version of Medical Outcomes Study Social Support Survey.27

#### Physical Activity, Falls, and Fractures

Physical activity level, operationalized as frequency of engagement in light, moderate, and vigorous physical activity, was evaluated using the abbreviated Physical Activity Scale for the Elderly.28 Fall history was assessed via a single question regarding a history of falls within the past 12 months. Fracture history was assessed by asking patients whether they had broken a bone since turning 50. Fracture risk was evaluated using selected questions from the Fracture Risk Assessment Tool (FRAX)29 and the International Osteoporosis Foundation’s One Minute Risk Check.30

#### Post-Discharge Recovery and Events

At follow-up interviews, we collected information from patients about hospital readmissions, emergency department visits, receipt of home health care, receipt of physical or occupational therapy, admission to short-term rehabilitation, fractures during the follow-up period, and restricted activity.

### Medical Record Data

Patient-reported data were supplemented with data from the electronic health record. We obtained granular data about the index hospitalization from the Yale Department of Medicine COVID-19 Data Explorer (DOM-CovX)31, which contains health record data from all patients admitted to a YNHHS hospital with a positive SARS-CoV-2 test. Data in the DOM-CovX registry include information about use of specific treatments for COVID-19, such as corticosteroids and remdesivir; severity of illness, as determined by the Sequential Organ Failure Assessment (SOFA) score;32 need for advanced respiratory support; and detailed laboratory data. The DOM-CovX registry also provided data about demographics, medical comorbidities, and discharge disposition. Missing data from the registry were filled in via manual chart abstraction, when possible. We supplemented the DOM-CovX registry with additional structured data about delirium, measured by the Confusion Assessment Method (CAM)33 or CAM-ICU34 and collected as part of routine clinical practice by hospital nursing staff, through a separate electronic health record data pull. We performed additional manual chart abstraction to capture other variables, including information about COVID-19 vaccination status at baseline and follow-up. The Area Deprivation Index, a detailed measure of the socioeconomic conditions in a specific geographical area, was calculated based on each participant’s zip code using the Neighborhood Atlas.35

### Data Management

Research Electronic Data Capture (REDCap) software was used for all study workflow organization and data management activities.36 Specialized features were developed by the REDCap@Yale team (P.C., S.C., K.A.) at the Yale Claude D. Pepper Older Americans Independence Center. Participant workflow was managed using a custom REDCap dashboard, which incorporated key automation and quality control measures to optimize efficiency of study assessments and accuracy of data collection. Data collection forms utilized integrated quality control checks to identify data entry errors and out-of-range values. DOM-CovX registry data were imported into REDCap. An automated routine created SAS datasets for all study reports, quality control checks, and analyses. Missing data were evaluated for all variables and were addressed using multiple imputation, as appropriate. As diagnostic algorithms for COVID-19 in older adults evolved rapidly, the majority of missing data involve laboratory tests that were introduced or omitted from the YNHHS diagnostic order sets over the course of the study.

### Statistical Analysis

Baseline characteristics of VALIANT participants were summarized using means and standard deviations for normally distributed continuous variables, medians and interquartile ranges for ordinal or non-normally distributed continuous variables, and proportions for categorical variables. Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).

### Data Sharing

Data from VALIANT will be made available to the public, for use upon approval by the principal investigators, at one year from completion of data collection (January 31, 2023).

## Results

Between June 18, 2020 and June 30, 2021, we screened 1,747 older adults at five hospitals. Among them, 939 were deemed eligible, 680 consented, and 341 were enrolled (**Figure 2)**. There were no differences in demographic characteristics between the screened and enrolled participants. Characteristics of the enrolled participants are presented in **Table 1**. The mean age was 71.4 (standard deviation [SD] 8.4) years, 175 (51.3%) were women, and 125 (36.6%) were of Black race or Hispanic ethnicity. Nearly one third of participants had Medicaid as one of their forms of insurance. Most participants lived at home, with 239 (70.5%) reporting that they lived with others and 92 (27.1%) reporting that they lived at home alone.

![Figure 2.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/09/15/2022.09.14.22279932/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279932/F2)

Figure 2. 
Screening and enrollment flow diagram for participants in VALIANT.

View this table:
[Table 1.](http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279932/T1)

Table 1. 
Sociodemographic characteristics of VALIANT participants

Clinical and functional characteristics of study participants before their hospital admission with COVID-19 are provided in **Table 2**. Participants had a median of three comorbidities (interquartile range [IQR] 1-4), and 157 (46.6%) reported having at least one disability in the month prior to hospitalization. Of the 301 participants with complete frailty data, 56 (18.6%) were frail, 147 (48.8%) were pre-frail, and 98 (32.6%) were not frail. There were 52 participants (15.2%) who had received at least one dose of a COVID-19 vaccine before being hospitalized.

View this table:
[Table 2.](http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279932/T2)

Table 2. 
Clinical characteristics of VALIANT participants prior to COVID-19 hospitalization

Clinical characteristics of study participants during their hospitalization with COVID-19 are shown in **Table 3**. Most were hospitalized on the general wards; however, 40 (11.7%) participants required ICU admission, and 29 (8.5%) required stepdown unit care. Sixty (17.6%) participants required advanced respiratory support with either high-flow nasal cannula, non-invasive positive pressure ventilation, or invasive mechanical ventilation during their hospitalization. Of the remaining participants, 78.0% required low-flow supplemental oxygen and 4.4% did not require oxygen support. The median hospital length of stay was eight (IQR 6-12) days. Of the 40 participants admitted to the ICU, the median ICU length of stay was 7 (IQR 4-15) days.

View this table:
[Table 3.](http://medrxiv.org/content/early/2022/09/15/2022.09.14.22279932/T3)

Table 3. 
Clinical characteristics of VALIANT participants during COVID-19 hospitalization

The majority of participants (239, or 70.1%) received a corticosteroid during their hospitalization, which in most cases was dexamethasone. Remdesivir was administered to 246 (72.1%) participants and tocilizumab to 68 (19.9%) participants. Considering the maximum value reported for each study participant during hospitalization, the median D-Dimer was 1.4 (IQR 0.8-3.4) mg/L Fibrinogen Equivalent Units and the median interleukin-6 (IL-6) value was 20.6 (IQR 8.9-58.6) pg/mL, although IL-6 values were missing for 101 patients. During the baseline interview, participants reported a mean of 9 (SD 3) out of 14 possible COVID-19-related symptoms and an average symptom burden of 19 (SD 9), out of a maximum of 42, when each symptom was graded according to severity. There were 124 (45.3%) participants who had a score of <22 on the MoCA 5-minute protocol, suggestive of cognitive impairment. Delirium was present in 23 (6.7%) participants.

## Discussion

We designed and conducted VALIANT to provide detailed, high-quality data about the health outcomes of older adults who have survived a COVID-19 hospitalization. We placed particular emphasis on evaluating the outcomes that matter most to older persons, including preservation of physical function and cognition as well as freedom from burdensome symptoms.10 Among the 341 participants we enrolled, there were high rates of baseline functional disability, high rates of cognitive impairment, and high symptom burden. The frequent and detailed assessments performed following hospital discharge will provide a rich opportunity to examine these issues and how they change over the six months after participants left the hospital.

There is a considerable and growing body of literature examining clinical outcomes following COVID-19 infection. Prior research has used administrative data to examine the post-acute sequelae of disease37 and to describe functional impairment among COVID-19 survivors who receive home health care services.38 There have been studies assessing persistent symptoms following hospitalization,39, 40 the development of new disability,41, 42 and cognitive impairment,43 with investigators in the Post-Hospitalization COVID-19 Study recently using cluster analysis to identify four distinct recovery phenotypes among a large of cohort of patients discharged from a hospital in the United Kingdom.44 VALIANT adds to this work in several important ways. First, we specifically focused on older patients, who are much more likely to have serious illness with COVID-19 and are also at much greater risk of functional and cognitive impairment following hospitalization.45, 46 The mean age of our cohort, 71.4 years, is substantially higher than those of prior studies. Second, existing cohorts of COVID-19 survivors have nearly all collected data during a single interview.41, 43, 44 One exception involves patients in Wuhan, China, who were hospitalized early in the COVID-19 pandemic and then evaluated at 6 and 12 months after infection.47 This cohort was considerably younger than ours, however, and participants did not undergo assessment at the time of hospitalization or provide information about function or cognition. VALIANT was designed to overcome these limitations by including a baseline interview, performed during or as close to the acute illness as possible, and by obtaining repeated interviews during the six months following hospital discharge. Since the available evidence suggests that recovery among older persons is highly dynamic, with frequent transitions between states of disability and independence,48 this approach will allow us to shed new light on the trajectories of function, cognition, and symptom burden that older adults experience following hospitalization with COVID-19. We expect that these high-quality data will guide the development of interventions to improve the health and well-being of older survivors and to contribute to the evidence base that informs medical decisions for these patients.

Our study has several additional strengths. COVID-19 has caused serious illness disproportionately in historically marginalized racial and ethnic groups that have often been reluctant to engage in medical research.49 The racial and ethnic makeup of the VALIANT cohort approximates the racial and ethnic makeup of the two counties from which most participants were recruited.50 Specifically, more than 20% of participants were Black and more than 13% were Hispanic. In addition, participants were socioeconomically diverse, with 30% covered by Medicaid, and their baseline health characteristics mirror the heterogeneity of older adults seen in clinical practice. Participants had a median of three chronic conditions, nearly half were disabled in at least one functional activity prior to hospitalization, and a majority were frail or pre-frail. Additionally, there were minimal missing data, except in laboratory values that were eliminated from the standard hospital order set during the study period.

There are two important limitations to these data. The first is that all assessments were conducted remotely. While the study team initially planned to conduct the final, six-month visit in person, this proved infeasible because of restrictions put in place during the pandemic. We instead constructed study interviews with items that could be measured reliably and with high validity via telephone or videoconference. The second is that, while most eligible patients agreed to participate, only slightly more than half of consented patients completed the baseline assessment, despite efforts by our highly experienced and dedicated research staff. Research personnel reported that many patients simply felt too sick during their infection with COVID-19 to participate in a research study. This raises the possibility that our cohort is biased towards patients who were less ill during hospitalization, and, indeed, only 20% of VALIANT participants were admitted to an ICU or stepdown unit. However, nearly all required supplemental oxygen, the majority qualified for corticosteroids and remdesivir, and the median hospital length of stay was eight days — characteristics that reflect the presence of severe illness.

In conclusion, VALIANT is a unique longitudinal study of older adults who have survived hospitalization with COVID-19. It contains granular measures, reported during acute illness and then at multiple time points afterward, that were selected to provide evidence about the health outcomes that matter most to older persons. We anticipate that the knowledge gained from this rich resource will ultimately help guide the development of interventions directed at improving the health of older COVID-19 survivors.

## Supporting information

Supplementary Material [[supplements/279932_file02.pdf]](pending:yes)

## Data Availability

Data from VALIANT will be made available to the public, for use upon approval by the principal investigators, at one year from completion of data collection (January 31, 2023).

## Conflicts of interest

No conflicts of interest to disclose.

## Author contributions

Study concept and design — Cohen, Hajduk, Ferrante.

Acquisition of subjects and data — Cohen, Geda, Lee, Hajduk, Ferrante.

Analysis and interpretation of data — All authors.

Preparation of manuscript — All authors.

## Sponsor’s role

This work was supported by the Claude D. Pepper Older Americans Independence Center at Yale University (P30AG21342 and P30AG21342-18S1). Dr. Cohen and Dr. Ferrante were supported by Paul B. Beeson Emerging Leaders in Aging awards (K76AG059987 and K76AG057023) from the National Institute on Aging. The funding sources were not involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript.

## Other acknowledgments

For help with participant recruitment and interviews, the authors express their gratitude to the members of the Operations Core at the Yale Claude D. Pepper Older Americans Independence Center, including Andrea Benjamin, Sandi Capelli, Amanda Dressel, Kizzy Hernandez-Bigos, Emily Marry, Bridget Mignosa, Amy Shelton, and Maria Zenoni. The authors also wish to thank Harry Doernberg for assistance with chart reviews and the Joint Data and Analytics Team at Yale School of Medicine for assistance with accessing data from the electronic health record. We would like to thank the Yale Department of Medicine COVID-19 Explorer data repository, which was made possible by funding from the Department of Medicine, the George M. O’Brien Kidney Center at Yale (P30DK079310), resources from the Clinical and Translational Research Accelerator, and collaboration with the Yale Center for Clinical Investigation.

## Acknowledgements

## Footnotes

*   *Funding sources*: This work was supported by the Claude D. Pepper Older Americans Independence Center at Yale University (P30AG21342 and P30AG21342-18S1). Dr. Cohen and Dr. Ferrante were supported by Paul B. Beeson Emerging Leaders in Aging awards (K76AG059987 and K76AG057023) from the National Institute on Aging.

*   Received September 14, 2022.
*   Revision received September 14, 2022.
*   Accepted September 15, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## References

1.  1.Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369: m1966.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE4OiIzNjkvbWF5MjJfMTUvbTE5NjYiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wOS8xNS8yMDIyLjA5LjE0LjIyMjc5OTMyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

2.  2.National Center for Health Statistics, Centers for Disease Control and Prevention. COVID-19 Mortality Overview. Available at: [https://www.cdc.gov/nchs/covid19/mortality-overview.htm](https://www.cdc.gov/nchs/covid19/mortality-overview.htm). Accessed June 24, 2022.
    
    

3.  3.Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021;4: e210417.
    
    

4.  4.Hadley EC, Kuchel GA, Newman AB, et al. Report: NIA workshop on measures of physiologic resiliencies in human aging. J Gerontol A Biol Sci Med Sci. 2017;72: 980–990.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/gerona/glx015&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

5.  5.Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35: 75–83.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/epirev/mxs009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23372025&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000315703400007&link_type=ISI) 

6.  6.Creditor MC. Hazards of hospitalization of the elderly. Ann Intern Med. 1993;118: 219–223.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/0003-4819-118-3-199302010-00011&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8417639&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1993KJ43900011&link_type=ISI) 

7.  7.Matalon N, Dorman-Ilan S, Hasson-Ohayon I, et al. Trajectories of post-traumatic stress symptoms, anxiety, and depression in hospitalized COVID-19 patients: A one-month follow-up. J Psychosom Res. 2021;143: 110399.
    
    

8.  8.Kennedy M, Helfand BKI, Gou RY, et al. Delirium in older patients with COVID-19 presenting to the emergency department. JAMA Netw Open. 2020;3: e2029540.
    
    

9.  9.Falvey JR, Ferrante LE. Flattening the disability curve: Rehabilitation and recovery after COVID-19 infection. Heart Lung. 2020.
    
    

10. 10.Fried TR, Tinetti ME, Iannone L, O’Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med. 2011;171: 1854–1856.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archinternmed.2011.424&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21949032&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000297056300016&link_type=ISI) 

11. 11.von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61: 344–349.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jclinepi.2007.11.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18313558&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000253998200007&link_type=ISI) 

12. 12.Jeste DV, Palmer BW, Appelbaum PS, et al. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007;64: 966–974.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archpsyc.64.8.966&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17679641&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000248542600011&link_type=ISI) 

13. 13.Gill TM, Allore H, Guo Z. Restricted activity and functional decline among community-living older persons. Arch Intern Med. 2003;163: 1317–1322.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archinte.163.11.1317&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12796067&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000183390600008&link_type=ISI) 

14. 14.Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9: 179–186.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.1093/geront/9.3_Part_1.179&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=5349366&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1969E667100003&link_type=ISI) 

15. 15.Gill TM. Disentangling the disabling process: insights from the precipitating events project. Gerontologist. 2014;54: 533–549.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/geront/gnu067&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25035454&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

16. 16.Wong A, Nyenhuis D, Black SE, et al. Montreal Cognitive Assessment 5-minute protocol is a brief, valid, reliable, and feasible cognitive screen for telephone administration. Stroke. 2015;46: 1059–1064.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToic3Ryb2tlYWhhIjtzOjU6InJlc2lkIjtzOjk6IjQ2LzQvMTA1OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA5LzE1LzIwMjIuMDkuMTQuMjIyNzk5MzIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

17. 17.Masika GM, Yu DSF, Li PWC, Wong A, Lin RSY. Psychometrics and diagnostic properties of the Montreal Cognitive Assessment 5-min protocol in screening for Mild Cognitive Impairment and dementia among older adults in Tanzania: A validation study. Int J Older People Nurs. 2021;16: e12348.
    
    

18. 18.Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7: 6–9.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1714502&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

19. 19.Walke LM, Byers AL, McCorkle R, Fried TR. Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manage. 2006;31: 31–37.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jpainsymman.2005.05.014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16442480&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000235422300007&link_type=ISI) 

20. 20.Ware J, Jr.., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34: 220–233.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/00005650-199603000-00003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8628042&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1996TZ57700003&link_type=ISI) 

21. 21.Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56: M146–156.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/gerona/56.3.M146&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11253156&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000167294000010&link_type=ISI) 

22. 22.Palmer KT, D’Angelo S, Harris EC, et al. Frailty, prefrailty and employment outcomes in Health and Employment After Fifty (HEAF) Study. Occup Environ Med. 2017;74: 476–482.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToib2VtZWQiO3M6NToicmVzaWQiO3M6ODoiNzQvNy80NzYiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wOS8xNS8yMDIyLjA5LjE0LjIyMjc5OTMyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

23. 23.Bandeen-Roche K, Seplaki CL, Huang J, et al. Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci. 2015;70: 1427–1434.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/gerona/glv133&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26297656&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

24. 24.Kuo PL, Huang AR, Ehrlich JR, et al. Prevalence of concurrent functional vision and hearing impairment and association with dementia in community-dwelling Medicare beneficiaries. JAMA Netw Open. 2021;4: e211558.
    
    

25. 25.Ferrante LE, Pisani MA, Murphy TE, Gahbauer EA, Leo-Summers LS, Gill TM. Factors associated with functional recovery among older intensive care unit survivors. Am J Respir Crit Care Med. 2016;194: 299–307.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1164/rccm.201506-1256OC&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

26. 26.Kroenke K, Spitzer RL, Williams JB, Lowe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50: 613–621.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1176/appi.psy.50.6.613&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19996233&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000272488900010&link_type=ISI) 

27. 27.McCarrier KP, Bushnell DM, Martin ML, Paczkowski R, Nelson DR, Buesching DP. Validation and psychometric evaluation of a 5-item measure of perceived social support. Value in Health. 2011;14.
    
    

28. 28.Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46: 153–162.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/0895-4356(93)90053-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8437031&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1993KP70500004&link_type=ISI) 

29. 29.Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19: 385–397.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00198-007-0543-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18292978&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000253995100002&link_type=ISI) 

30. 30.Kharroubi A, Saba E, Ghannam I, Darwish H. Evaluation of the validity of osteoporosis and fracture risk assessment tools (IOF One Minute Test, SCORE, and FRAX) in postmenopausal Palestinian women. Arch Osteoporos. 2017;12: 6.
    
    

31. 31.Arora T, Simonov M, Alausa J, et al. The Yale Department of Medicine COVID-19 Data Explorer and Repository (DOM-CovX): An innovative approach to promoting collaborative scholarship during a pandemic. medRxiv. 2021: 2021.2008.2023.21262241.
    
    

32. 32.Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009;37: 1649–1654.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CCM.0b013e31819def97&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19325482&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000265368900014&link_type=ISI) 

33. 33.Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113: 941–948.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/0003-4819-113-12-941&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=2240918&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1990EM29700008&link_type=ISI) 

34. 34.Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286: 2703–2710.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.286.21.2703&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11730446&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000172488300030&link_type=ISI) 

35. 35.Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible: the Neighborhood Atlas. N Engl J Med. 2018;378: 2456–2458.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMp1802313&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29949490&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

36. 36.Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jbi.2019.103208&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31078660&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

37. 37.Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594: 259–264.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

38. 38.Bowles KH, McDonald M, Barron Y, Kennedy E, O’Connor M, Mikkelsen M. Surviving COVID-19 after hospital discharge: Symptom, functional, and adverse outcomes of home Health recipients. Ann Intern Med. 2021;174: 316–325.
    
    

39. 39.Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021;325:1525–1534. DOI: 10.1001/jama.2021.3331
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2021.3331&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

40. 40.Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174: 576–578.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-5661&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33175566&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

41. 41.Qin ES, Gold LS, Hough CL, et al. Patient-reported functional outcomes 30 days after hospitalization for COVID-19. PM R. 2021; 14: 173–172.
    
    

42. 42.Hodgson CL, Higgins AM, Bailey MJ, et al. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study. Crit Care. 2021;25: 382.
    
    

43. 43.Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open. 2021;4: e2130645.
    
    

44. 44.Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9: 1275–1287.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

45. 45.Gill TM, Allore HG, Gahbauer EA, Murphy TE. Change in disability after hospitalization or restricted activity in older persons. JAMA. 2010;304: 1919–1928.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2010.1568&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21045098&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000283725900022&link_type=ISI) 

46. 46.Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA. Cognitive decline after hospitalization in a community population of older persons. Neurology. 2012;78: 950–956.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0b013e31824d5894&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22442434&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

47. 47.Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398: 747–758.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(21)01755-4/ATTACHMENT/5440AE6D-9DED-4100-8EE6-77F72BA95154/MMC1.PDF&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

48. 48.Hardy SE, Dubin JA, Holford TR, Gill TM. Transitions between states of disability and independence among older persons. Am J Epidemiol. 2005;161: 575–584.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/aje/kwi083&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15746474&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000227406100009&link_type=ISI) 

49. 49.Lopez L, 3rd., Hart LH, 3rd., Katz MH. Racial and ethnic health disparities related to COVID-19. JAMA. 2021;325: 719–720.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.26443&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F15%2F2022.09.14.22279932.atom) 

50. 50.Connecticut Department of Public Health. Population Statistics. Available at: [https://portal.ct.gov/dph/Health-Information-Systems--Reporting/Population/Population-Statistics](https://portal.ct.gov/dph/Health-Information-Systems--Reporting/Population/Population-Statistics). Accessed June 24, 2022.